News

  • Aspira Women’s Health Announces the Commercial Launch of OvaWatch(SM)

     November 29, 2022 16:01 ET  AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, announced the commercial launch of OvaWatchSM, a new non-invasive blood-based test for the assessment of ovarian cancer risk in women with adnexal masses. OvaWatch is part of…

  • Aspira Women’s Health Reports Third Quarter 2022 Financial Results

     November 10, 2022 07:00 ET  Increased year-over-year product revenue by 26% to $2.0 million and year-over-year product volume by 29% to 5,524 units Reconfirmed fourth quarter launch of OvaWatch ovarian cancer risk assessment and announced rebranding of the ovarian cancer product portfolio as OvaSuite Executed and fully funded a sponsored research agreement with Harvard’s Dana…

  • Aspira Women’s Health to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10

     November 01, 2022 08:00 ET  AUSTIN, Texas, Nov. 01, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that the company will report its financial results for the third quarter ended September 30, 2022 before the market open on Thursday, November 10, 2022. Management will also host…

  • Aspira Women’s Health to Participate at the Upcoming MicroCap Rodeo Windy City Roundup 2022

     October 06, 2022 16:05 ET  AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that management will present and be available for 1×1 meetings at the MicroCap Rodeo Presents Windy City Roundup 2022 conference taking place in-person on October 12-13, 2022 in Chicago,…

  • Aspira Women’s Health Announces Formal Launch of Co-Marketing and Distribution Collaboration with BioReference

    OVA1Plus® now available to an expanded network of physicians, supporting patients nationwide  October 05, 2022 08:00 ET  AUSTIN, Texas, Oct. 05, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the formal launch of its co-marketing and distribution collaboration with BioReference®, an OPKO…

  • Aspira Women’s Health Announces Publication of its Second-Generation MultiVariate Index Assay, OVERA®, in the Detection of Cancer in Filipino Women

    Data demonstrates the accuracy of Aspira’s multivariate assessment test OVERA in a non-White population and concludes use of OVERA to be better than CA-125 in detecting early-stage cancer in women with a pelvic mass  September 12, 2022 16:28 ET  AUSTIN, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based…

  • Aspira Women’s Health Inc. Announces Pricing of $9.0 Million Public Offering

     August 23, 2022 08:00 ET  AUSTIN, Texas, Aug. 23, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the pricing of the previously announced underwritten public offering of 12,000,000 shares of its common stock and warrants to purchase an aggregate of…

  • Aspira Women’s Health Inc. Announces Proposed Public Offering

     August 22, 2022 16:02 ET  AUSTIN, Texas, Aug. 22, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. The…

  • Aspira Women’s Health Hosting Women’s Health Webinar on Ovarian Cancer Risk Assessments Utilizing Multivariate Index Assay

    KOL Event to take place on Wednesday, August 24th at 12:00pm ET  August 18, 2022 16:05 ET  AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced that it will host a key opinion leader (KOL) webinar on women’s health…

  • Aspira Women’s Health Reports Second Quarter 2022 Financial Results

     August 10, 2022 07:30 ET  Increased product revenue by 17% to $2.0 million; Grew OVA1plus volume by 19% to 5,411 units Entered into a research agreement with Harvard’s Dana Farber Cancer Institute, Brigham & Women’s Hospital, and Medical University of Lodz for development of a diagnostic test for endometriosis Reduced cash utilization by $3.9 Million…

  • Aspira Women’s Health to Announce Second Quarter 2022 Financial Results and Host Conference Call on Wednesday, August 10

     August 01, 2022 08:00 ET  AUSTIN, Texas, Aug. 01, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced that the company will report its financial results for the second quarter ended June 30, 2022 before the market open on Wednesday, August 10, 2022.…

  • Aspira Women’s Health Announces Appointment of Two New Board Members

    Seasoned Directors further strengthen Board with decades of industry and leadership experience June 23, 2022 16:05 ET AUSTIN, Texas, June 23, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the appointments of two seasoned Board members: Dr. Robert Auerbach and Ms. Ruby Sharma. Dr

  • Aspira Women’s Health Announces Publication of Paper Validating OvaWatch™ Algorithm in the Detection of Ovarian Cancer

    Paper published in the June online issue of JCO Clinical Cancer Informatics June 16, 2022 16:01 ET AUSTIN, Texas, June 16, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the online publication of a paper validating its OvaWatch™ algorithm in the detection of…

  • Aspira Women’s Health to Participate in the Upcoming Investor Conferences

    AUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that management will participate in the “MicroCap Rodeo Spring Into Action Best Ideas” Conference virtually and the “William Blair 42nd Annual Growth Stock Conference” in Chicago. Details for both investor conferences are below: William…

  • Aspira Women’s Health Reports First Quarter 2022 Financial Results

    May 11, 2022 07:30 ET Product Revenue Increased 30% to $1.8 million; OVA1plus Volume Grew 28% to 4,819 Units New Ordering Physicians in the First Quarter Grew 47% to 603 Year Over Year Board and Leadership appointments announced Conference Call and Webcast scheduled for today, May 11th at 8:30 a.m. ET AUSTIN, Texas, May 11,…

  • Aspira Women’s Health Reports Fourth Quarter and Full Year 2021 Financial Results

    Total Revenue Increased 46% to $6.8 million; OVA1 Volume Grew 28% to 17,359 Units Exercise of option in the Harvard Dana-Farber Cancer Institute Collaboration Leadership and Board appointments implemented in First Quarter of 2022 Conference Call and Webcast scheduled for today, March 23rd at 8:30 a.m. ET AUSTIN, Texas —March 23, 2022 — Aspira Women’s…

  • Aspira Women's Health to Announce Year End 2021 Financial Results and Host Conference Call on Wednesday, March 23rd

    AUSTIN, Texas —March 15, 2022 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that the company will report its financial results for the year ended December 31, 2021 before the market open on Wednesday, March 23, 2022. Management will also host a conference call with investors to discuss financial…

  • Aspira Women’s Health Announces Appointment of Celeste Fralick, Ph.D., to its Board of Directors

    AUSTIN, Texas —Feb. 28, 2022 — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced the appointment of Celeste Fralick, Ph.D., to its Board of Directors, effective February 23, 2022. Dr. Fralick is an accomplished executive with over four decades of data strategy experience. She brings to the Board a broad…

  • Valerie Palmieri Elevated to Executive Chair of the Board; Nicole Sandford Appointed President and CEO

    Expanded leadership team to drive strategic partnerships, accelerate new commercial launches, and grow overall enterprise value AUSTIN, Texas —February 25, 2022 — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today named Valerie Palmieri as Executive Chair of the Board, and Nicole Sandford as President and CEO of the Company. Jim LaFrance,…

  • Aspira Women’s Health, Inc. Expands Senior Leadership Team with Addition of Mr. Michael Newton as Head of Sales and Marketing

    AUSTIN, Texas — February 22, 2022 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company today announced the appointment of Mr. Michael Newton as Head of Sales and Marketing who brings to the company over twenty years of experience in the diagnostic healthcare area. In this role, Mr. Newton will be responsible…

  • Aspira Women’s Health Announces the Addition of 465,000 Covered Lives Through Medicaid Credentialing

    AUSTIN, Texas — January 31, 2022 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, announced today that it has entered into agreements to provide its testing services to Medicaid plan members in the state of New Hampshire and Washington, D.C equaling nearly a half million covered lives.  The state of New Hampshire covers…

  • Aspira Women’s Health Appoints Minh Merchant as General Counsel

    AUSTIN, Texas —Jan. 5, 2022 — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that Minh Merchant will join the Company as General Counsel and Corporate Secretary, effective Jan. 4, 2022. In this role, Ms. Merchant will lead the Company’s legal, compliance, and enterprise risk management functions, reporting to Valerie…

  • Aspira Women’s Health Executes an Agreement with Axia Women’s Health to Launch Aspira Synergy Genetics Platform

    Axia Women’s Health is one of the largest women’s health networks in the United States serving nearly half a million women a year AUSTIN, Texas —January 5, 2022 — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, announced today that it has entered into a commercial enterprise agreement with Axia Women’s Health,…

  • Aspira Women’s Health Announces Fourth Quarter Operational Metrics and Provides Updates on Its OvaWatch and EndoCheck Programs

    Fourth quarter OVA1 volume grew 23.4% to 4,750 units Plans underway for staged launches of EndoCheck and OvaWatch AUSTIN, Texas —Jan 5, 2022 — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced preliminary fourth quarter operational results and provided a corporate update. Operational Metrics Update OVA1® volume in the fourth…

  • Aspira Women’s Health Reports Third Quarter 2021 Financial Results

    Total Revenue Increased 34% to $1.67 million; OVA1 Volume Grew 19% to 4,281 Units Successful completion of Proof of Concept with Harvard Dana Farber Cancer Institute Collaboration Achieved Over 194 Million Covered Lives for OVA1 Conference Call and Webcast Today at 8:30 a.m. ET For a link to a pdf of this press release please…